Vaccine crisis-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Qy98
2021-06-17

Vaccine crisis

Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute

Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the

Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":161275762,"tweetId":"161275762","gmtCreate":1623932292856,"gmtModify":1703823796409,"author":{"id":3581730059713664,"idStr":"3581730059713664","authorId":3581730059713664,"authorIdStr":"3581730059713664","name":"Qy98","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Vaccine crisis</p></body></html>","htmlText":"<html><head></head><body><p>Vaccine crisis</p></body></html>","text":"Vaccine crisis","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/161275762","repostId":1195023201,"repostType":4,"repost":{"id":"1195023201","pubTimestamp":1623930270,"share":"https://www.laohu8.com/m/news/1195023201?lang=&edition=full","pubTime":"2021-06-17 19:44","market":"us","language":"en","title":"Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=1195023201","media":"benzinga","summary":"Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the","content":"<ul>\n <li>Serum Institute of India (SII) is&nbsp;yet to receive raw materials&nbsp;from the U.S. required to produce the&nbsp;<b>Novavax Inc</b>&nbsp;vaccine despite diplomatic interventions by India, said an official aware of the development.</li>\n <li>The delay in receiving raw materials such as bioreactor bags and enzymes means that SII's launch of the Novavax vaccine, dubbed Covovax in India, will not likely happen before&nbsp;September, as planned initially.</li>\n <li>The company said raw material shortages have led to the delay in launching the vaccine.</li>\n <li>The U.S. lifted the export ban on raw materials on June 4.</li>\n <li>SII is the manufacturing partner for Novavax in India, where the firm has committed to producing up to 1 billion doses.</li>\n <li>Also, the Serum Institute of India plans to start clinical trials of the Novavax shot for children in July, according to&nbsp;ANI quoting sources.</li>\n <li>Earlier this week, NVAX's COVID-19 vaccine&nbsp;demonstrated 90% efficacy.</li>\n <li><b>Price Action:</b>NVAX shares are up 5.9% at $186.68 during the premarket trading session on the last check Thursday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the Novavax Inc vaccine despite diplomatic interventions by India, said an official aware of the ...</p>\n\n<a href=\"https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195023201","content_text":"Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the Novavax Inc vaccine despite diplomatic interventions by India, said an official aware of the development.\nThe delay in receiving raw materials such as bioreactor bags and enzymes means that SII's launch of the Novavax vaccine, dubbed Covovax in India, will not likely happen before September, as planned initially.\nThe company said raw material shortages have led to the delay in launching the vaccine.\nThe U.S. lifted the export ban on raw materials on June 4.\nSII is the manufacturing partner for Novavax in India, where the firm has committed to producing up to 1 billion doses.\nAlso, the Serum Institute of India plans to start clinical trials of the Novavax shot for children in July, according to ANI quoting sources.\nEarlier this week, NVAX's COVID-19 vaccine demonstrated 90% efficacy.\nPrice Action:NVAX shares are up 5.9% at $186.68 during the premarket trading session on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":13,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}